Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms
Author:
Affiliation:
1. School of Medicine, Dentistry & Nursing, University of Glasgow, Glasgow, UK
2. Centre for Reproductive Health, Institute for Repair and Regeneration, University of Edinburgh, Edinburgh, UK
Funder
No funding
Publisher
Informa UK Limited
Link
https://www.tandfonline.com/doi/pdf/10.1080/13543784.2024.2305122
Reference59 articles.
1. Symptoms of menopause — global prevalence, physiology and implications
2. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition
3. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women
4. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women
5. The 2022 hormone therapy position statement of The North American Menopause Society
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms;Expert Opinion on Pharmacotherapy;2024-05-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3